Retatrutide HA explained: what this experimental triple-agonist peptide does, how long it takes to work, dosing research, and safety facts to know.
Retatrutide is an investigational once-weekly injection from Eli Lilly that activates three hormone receptors at the same time: GLP-1, GIP, and glucagon. It is not FDA-approved for any use, and phase 3 trials are still running. Searches for "retatrutide HA" usually reflect three different questions — the drug's half-life, hair-related side effects, and plain curiosity about how the medication works — so this guide covers all three along with the core facts.
What Is Retatrutide?
Retatrutide (research code LY3437943) is a synthetic peptide designed to mimic three naturally occurring gut and metabolic hormones. It is injected subcutaneously once a week, similar to semaglutide and tirzepatide.
Unlike older single-receptor drugs, the glucagon component is intentional. Glucagon activity appears to raise energy expenditure and support fat loss, while GLP-1 and GIP drive appetite suppression and improved blood sugar control. That combination is the main reason researchers are paying attention.
Retatrutide is still an experimental compound in clinical development. It is not available by prescription, and any product sold online as "retatrutide" is unverified and should be treated with caution.
Is Retatrutide a GLP-3?
No. There is no clinically recognized "GLP-3" receptor or drug class; the phrase is marketing shorthand rather than a scientific category. The question is retatrutide a glp-3 comes up often because the drug hits more than one incretin pathway, which makes it sound like a next-generation upgrade.
The accurate label is triple agonist. Retatrutide binds and activates:
- GLP-1 — slows stomach emptying, reduces appetite, and improves glucose-dependent insulin release.
- GIP — works alongside GLP-1 on satiety and insulin sensitivity.
- Glucagon — increases energy use and fat oxidation, balanced by the incretin signals.
If you see "GLP-3" in an advertisement or product listing, treat it as a red flag rather than a technical description.
How Long Does Retatrutide Take to Work?
In the phase 2 trial, participants reported reduced appetite within the first few weeks, but the drug was started low and increased slowly. Anyone asking how long does retatrutide take to work should expect a gradual curve, not an overnight change.
- Weeks 1–4: appetite and portion sizes often begin to shrink; scale weight may barely move.
- Weeks 4–12: steady weight loss usually becomes measurable as the dose escalates.
- Weeks 24–48: the largest average reductions appear, and trial data are reported at both checkpoints.
Dose escalation is deliberate. Jumping to a high dose early tends to increase nausea and vomiting without producing faster results.
Retatrutide Dosage and Brand Name: What Trials Used
There is no approved retatrutide dosage, because the drug has no approved label. In the phase 2 study, weekly doses ranged from 1 mg to 12 mg, titrated upward roughly every four weeks. Phase 3 programs use similar weekly schedules with a 12 mg maximum.
Retatrutide brand name: none exists yet. "Retatrutide" is the generic name, LY3437943 is the development code, and Eli Lilly has not announced a commercial brand. Any site claiming to sell a branded retatrutide is likely misrepresenting an unapproved compound.
The drug's half-life is roughly six days, which is why once-weekly dosing works.
| Weekly dose (phase 2) | Approximate average weight reduction at 48 weeks |
|---|---|
| 1 mg | About 9% |
| 4 mg | About 17% |
| 8 mg | About 23% |
| 12 mg | About 24% |
| Placebo | About 2% |
These are group averages from a single phase 2 trial, not predictions for any individual. Phase 3 results may differ.
How Retatrutide Compares With Cagrilintide and Tirzepatide
These compounds get grouped together because all are injectable, dosed weekly, and aimed at weight reduction. The comparison cagrilintide vs retatrutide vs tirzepatide is not apples-to-apples, however, since only tirzepatide is FDA-approved for weight management.
| Compound | Mechanism | Typical trial dosing | US approval status |
|---|---|---|---|
| Tirzepatide | GLP-1 + GIP dual agonist | 5–15 mg weekly | Approved (Zepbound for weight, Mounjaro for type 2 diabetes) |
| Retatrutide | GLP-1 + GIP + glucagon triple agonist | 1–12 mg weekly in trials | Investigational; not approved |
| Cagrilintide | Amylin analog, studied mainly with semaglutide | Weekly, in combination | Investigational; not approved alone |
Retatrutide has produced the largest average weight reductions reported so far among these investigational options, but cross-trial numbers cannot be compared directly because study populations, durations, and titration rules all differ.
Side Effects, Safety, and What "HA" Might Mean
The most common side effects in trials were gastrointestinal: nausea, diarrhea, vomiting, and constipation. They were dose-related, most frequent during dose increases, and generally mild to moderate.
Researchers also tracked heart-rate increases and reported a small number of participants with altered skin sensation (dysesthesia) at higher doses. Both findings need longer follow-up before conclusions can be drawn.
Retatrutide is not a treatment for any condition, and anyone considering a GLP-1-class medication should talk with a licensed healthcare professional about risks, benefits, and alternatives.
As for the "HA" in retatrutide HA, three explanations cover most searches:
- Hair loss — rapid weight loss from any cause, including bariatric surgery or incretin drugs, can trigger temporary shedding known as telogen effluvium. It is usually reversible.
- Half-life — about six days, which supports once-weekly injections.
- Hyaluronic acid — a skincare ingredient with no connection to retatrutide; the two simply get confused in search results.
The short version: retatrutide is a promising but unapproved triple agonist, its timeline is measured in months rather than days, and talk of "GLP-3" is a label, not a mechanism.
Frequently Asked Questions
Is retatrutide FDA approved in the United States?
No. Retatrutide is an investigational drug and has not been approved by the FDA for any indication, including weight loss. Phase 3 trials are ongoing, and no brand name has been announced. Products marketed online as retatrutide are unapproved and unverified.
Is retatrutide a GLP-3?
No. "GLP-3" is not a recognized clinical receptor class or drug category. Retatrutide is a triple agonist that activates the GLP-1, GIP, and glucagon receptors, which is different from a single or dual incretin drug.
How long does retatrutide take to work?
Appetite changes often appear within the first few weeks, but the drug is titrated slowly, so noticeable weight loss typically builds over 4 to 12 weeks. In the phase 2 trial, the largest average reductions were reported at 24 and 48 weeks. Individual results vary widely.
This page provides educational research information and does not replace medical advice, diagnosis, or treatment.